By Dani Kass ( August 18, 2023, 9:35 PM EDT) -- Teva Pharmaceuticals should be allowed to protect its generic exclusivity for its version of a Bausch Health unit's blockbuster irritable bowel syndrome treatment, Xifaxan, by intervening in a competitor's suit, the generic-drug giant has told a D.C. federal court....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.